Forxiga

dapagliflozin

Opinion

On 31 January 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Forxiga. The marketing authorisation holder for this medicinal product is AstraZeneca AB.

The CHMP adopted a new indication as follows: 1

“Forxiga is indicated in adults for the treatment of insufficiently controlled

  • type 2 diabetes mellitus as an adjunct to diet and exercise, to improve glycaemic control,
    • as monotherapy when metformin is considered inappropriate due to intolerance.
    • in addition to other medicinal products for the treatment of type 2 diabetes.
  • type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

For clinical study results with respect to populations studied, effects on glycaemic control and combinations with other medicinal products see sections 4.4, 4.5 and 5.1.”

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European Public Assessment Report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.


1 New text in bold.

 

Key facts

Name
Forxiga
Agency product number
EMEA/H/C/002322
International non-proprietary name (INN) or common name
  • dapagliflozin
Active substance
  • dapagliflozin propanediol monohydrate
Therapeutic area
Diabetes Mellitus, Type 2
Date opinion adopted
31/01/2019
Company name
AstraZeneca AB
Status
Positive
Application type
Post-authorisation

How useful was this page?

Add your rating
Average
1 rating